This article is more than 6 months old
05/04/2021
|
Alba Tobella

The Chinese Biopharmaceutical company Sinovac Biotech has built CoronaVac, an inactivated-virus vaccine using a non-infectious variant of the virus causing the disease, unable to infect but capable of triggering an immune response.

The results of phase III of the clinical trial, presented on the 5th of February, started on 21 July 2020 in Brazil, Turquey, Indonesia, and Chile, grouping 25.000 participants. The results indicated a 91,25% efficacy.

CoronaVac consists of 2-dose series that are administered with 14 days difference. Almost twenty countries mainly distributed between Latin America and Asia are immunising their population with this vaccine.

The most common side effect, according to the researchers, is pain at the injection site.

CoronaVac vaccine can be stored at a temperature between 2ºC and 8ºC for three years.

Vaccines
Whatsapp icono

Envia'ns per WhatsApp el que vulguis verificar i ens hi posarem
695 225 233

Educació en l'era de la desinformació
Projectes d'alfabetització mediàtica i informacional per promoure una ciutadania crítica
Desfake
Icone
Et necessitem

Amb la teva aportació contribuiràs a un debat polític més saludable i ajudaràs a impulsar projectes educatius per ensenyar a navegar el caos informatiu i a defensar-se de la desinformació.

Articles relacionats

  • Bacteria do not wait five seconds to jump onto your food after it falls on the floor

  • There is no proof that cracking your knuckles harms your joints

  • At-home genetics tests are accurate for determining ancestral origins, but not for predicting diseases

Especials

Nothing Found